Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series
Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms<sup>1</sup>. Therapies include chemotherapy or immunotherapy<sup>2-4</sup> though stem cell transplantation (SCT) is the best consolidative approach in eligible patients<sup>5</sup>. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN.
Authors
- Mürüvvet Seda Aydın (ORCID: https://orcid.org/0000-0002-7991-5275)
- Gülsüm Özet (ORCID: https://orcid.org/0000-0003-2658-5978)
- Simten Dağdaş (ORCID: https://orcid.org/0000-0003-0901-2043)
- Ahmet Kürşad Güneş (ORCID: https://orcid.org/0000-0001-5522-8342)
- Funda Ceran (ORCID: https://orcid.org/0000-0003-3173-7614)
- Esra Cengiz (ORCID: https://orcid.org/0000-0001-8583-778X)
Institutions
- Şanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- International Journal of Hematology-Oncology and Stem Cell Research
- Published
- 2025-02-10
- DOI
- https://doi.org/10.18502/ijhoscr.v19i1.17829
- Citations
- 1
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 2.00